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Abstract 
 
Objectives: A national audit assessing the impact and experience of early management of 
inflammatory arthritis by English and Welsh rheumatology units. 
Methods: All individuals >16 years presenting to English and Welsh rheumatology services with 
suspected new onset inflammatory arthritis were included in the audit. Clinician and patient derived 
outcome and patient reported experience measures were collected. 
Results: Data are presented for the 6,354 patients recruited from 1 February 2014 to 31 January 
2015. 97% of English and Welsh trusts participated. At first specialist assessment DAS28 was 
calculated for 2659 (91%) of RA patients, mean DAS28 was 5.0 and mean RAID score was 5.6. After 
3 months of specialist care mean DAS28 reduced to 3.5 and just over 60% achieved a meaningful 
DAS28 reduction. The average RAID score and reduction in RAID score was 3.6 and 2.4 respectively. 
 
Of the working patients aged 16-65 years providing data 7%, 5%, 16% and 37% reported that they 
were unable to work, needed frequent time off work, occasionally and rarely needed time off work due 
to their arthritis respectively; only 42% reported being asked about their work. 78% of RA patients 
providing data agreed with the statement “overall in the last 3 months I have had a good experience 
of care for my arthritis”; less than 2% disagreed. 
 
Conclusions: This audit demonstrates that most RA patients have severe disease at the time of 
presentation to rheumatology services and that a significant number continue to have high disease 
activity after 3 months of specialist care.. 
 
  
Objectives 
 
In 2009, the UK National Audit Office (NAO) reported the cost effectiveness of early aggressive 
treatment of RA but also significant geographical variation in RA care across the UK [1]. The UK 
National Institute for Health and Care Excellence (NICE) 2009 clinical guidance (CG79) [2] and 2013 
Quality Standards (QS33) [3] for the treatment of rheumatoid arthritis (RA) have emphasised the 
importance of early diagnosis and treatment of RA. 
In February 2014, the British Society for Rheumatology (BSR), with its information technology (IT) 
partner Northgate Public Services launched a Healthcare Quality Improvement Partnership (HQIP) 
funded national clinical audit of the management of early inflammatory arthritis (EIA). 
The audit aims to assess the early management of patients referred to English and Welsh 
rheumatology units with suspected inflammatory arthritis and to enable patients to provide feedback 
on the services provided to them and on the impact of their arthritis on their daily lives. The ability to 
work has been demonstrated to be highly important to individual’s health and welfare and to the wider 
economy so this was also assessed within this audit [4]. The audit enables rheumatology services to 
measure their performance, patient outcomes and experience, benchmarked to regional and national 
comparators for the first time. 
Methods 
The data collection tools were developed by the audit project working group and approved for use by 
HQIP and the NHS Review of Central Returns (ROCR), now renamed the Burden Advice and 
Assessment Service. There was a pilot of the questionnaires and web-based information technology 
(IT) tool prior to the audit launch in February 2014. Patient consent, using HQIP and ROCR approved 
processes,  was obtained at baseline and recorded for all analysed data. 
All individuals > 16 years presenting to specialist rheumatology services in England and Wales with 
new onset peripheral joint polyarthritis were included in the audit. Patients were recruited if they had 
RA, psoriatic arthritis, peripheral arthritis linked with spondyloarthropathy (not pure axial 
spondyloarthropathy) and undifferentiated arthritis but were excluded if they had crystal arthritis or 
arthritis caused by infection (viral or septic arthritis) or linked with connective tissue 
disorders/vasculitis. 
Clinician derived 28 joint disease activity scores (DAS 28) ) [5] were recorded, when assessed at 
appointments, at baseline and up to 3 months of specialist review for patients with an RA pattern of 
disease (defined by the presence of polyarticular disease (>5  joints involved) or pauciarticular 
disease with positive CCP antibodies). Follow up data capture was for Rheumatoid Arthritis (RA) 
patients only, given the quality standards being assessed are for RA 
Patient reported outcome and experience measures (PROMs and PREMs) and information on ability 
to work were also collected. 
The PROM used was the Rheumatoid Arthritis Impact of Disease (RAID) score [6]; a validated tool for 
RA patients. The RAID score is a patient-derived composite measure of the impact of RA, assessing 
pain, functional capacity, fatigue, physical and emotional wellbeing, quality of sleep and coping. The 
overall score ranges from 0 (best) to 10 (worst). PROM data was collected for all patients at 
presentation and after 3 months of specialist review for RA patients. Prior to this audit’s launch, there 
were no established tools for assessing work status in patients with inflammatory arthritis. Following 
consultation with experts in the field and with patient representatives, a short questionnaire was 
developed, agreed and piloted and was completed as part of the patient follow up questionnaire. 
Impact on a patient’s ability to work is presented for patients of working age i.e. 16-65 years. 
The PREM used was an adaptation for use at 3 months of the tool developed by Commissioning for 
Quality in Rheumatoid Arthritis (CQRA) group with the UK National Rheumatoid Arthritis Society for 
patients with RA ) [7]. To ensure confidential feedback PREM data was collected after 3 months of 
specialist review via individuals not involved in the patients care. The processes adopted were 
necessarily individual to individual trusts but, in general, were provided by non clinical audit staff. The 
PREM question analysed for this report was “overall in the past 3 months I have had a good 
experience of care for my arthritis” with responses categorised as agree (agree or strongly agree), 
neither agree nor disagree, disagree (disagree or strongly disagree) and not answered. Individual 
trusts have access to the full questionnaire responses. Translators required for any consultations 
were available to assist patients with their questionnaires. 
 
Achievement of the 7 NICE Quality Standards [3] and information on key factors potentially impacting 
on patient experience and outcomes (catchment population; numbers of whole time equivalent 
consultants and specialist staff; availability of EIA clinics) were also assessed and are reported 
separately [8]. 
The Medical Research Council (MRC) Lifecourse Epidemiology Unit in Southampton analysed the 
data. 
Results 
Data are presented for patients recruited from 1 February 2014 to 31 January 2015. 143 of 148 
eligible National Health Service (NHS) rheumatology providers in England and Wales registered to 
participate in the audit and 94% of these supplied data. Data from 6,354 patients were analysed, 
representing > 40% of expected incident RA cases. 
Details of the patient demographics, diagnoses and on departmental staffing levels per head of 
population are within a further submitted paper[7]. Patients were predominantly women (66%) and 
70% were of working age (aged 16-65 years). The majority of patients recruited were of white British 
origin (79%) but there was significant geographical variation in ethnicity. Forty-six percent (55% of 
patients with a confirmed diagnosis) had RA diagnosed at baseline. 
. 
DAS 28 Data 
Nationally, at the point of first specialist assessment, DAS 28 was calculated for the vast majority of 
RA patients (91%, 2659); when assessed within NHS regions and within Wales, DAS 28 was 
available for 99% of RA patients in Wales but for only 85% in the South of England. Mean DAS 28, 
the proportion of RA patients with high (>5.1), intermediate (3.2-5.1), low (<3.2) DAS 28 and with 
missing DAS 28 at baseline nationally and by NHS region is shown in table 1. The mean baseline 
DAS 28 was 5.0 with little regional variation (4.9 in the Midlands and East of England – 5.1 in the 
South of England and in Wales). Approximately half (45%) of patients had severe disease at 
presentation; Wales and the Midlands and East of England reported the highest (51%) and lowest 
(43%) proportion of patients with severe disease activity respectively. 
Table 2 show these data derived after 3 months of specialist care together with the proportion of RA 
patients in remission (DAS 28 <2.6) and achieving a meaningful reduction in DAS 28  [9]. Nationally 
the proportion of missing data at follow up increased to 28% (23% in London and the North of 
England and 39% in Wales). The mean DAS28 for RA patients had reduced to 3.5 for all regions. 
24% of RA patients at follow up were in remission (26% in Wales, 22% in the South of England and 
Midlands and East of England regions) but 11% still had high disease activity (14% in London, 8% in 
Wales). Nationally just over 60% of RA patients with available baseline and follow up DAS 28 
achieved a meaningful reduction in DAS 28 of >1.2; the highest and lowest achievement rates were 
observed in Wales and the North of England (67%) and the Midlands and East of England (57%) 
respectively. 
RAID data 
Table 3 summarises the national and NHS regional data for RAID scores supplied by all EIA patients 
at baseline and for those with RA at follow up. RAID scores indicated generally severe disease 
activity at the point of diagnosis with an EIA within rheumatology units; the mean score was 5.6 
nationally with a range of 5.5 (South of England) to 5.8 (Wales and the North of England). 
RAID data at follow up were available for 25% of patients with a confirmed RA pattern of disease.  
The national average RAID score at follow up was 3.6 with a wider range of scores (mean 3.1 in the 
North of England to 4.2 in Wales) supplied by patients at follow up than at baseline. The average 
reduction in RAID score nationally was 2.4 with the North of England achieving the highest (3.9) and 
Wales achieving the lowest (1.7) reductions in scores. At three months, these mean reductions fall 
short of the validated minimum clinically important difference for RAID (defined as a reduction of 3 
points or more or a percentage reduction of 50% from the baseline score) [10]. 
Work data 
Tables 4 and 5 summarise the data received from patients on their ability to work and on whether they 
recalled being asked about their work. Again very few patients (748) provided data and there was 
variation in data across the NHS regions.  26% of the patients aged 16-65 years that returned their 
patient questionnaires reported that they were not working but this was not because of their arthritis or 
that they were undertaking voluntary work. Of the remaining patients of working age that provided 
data: 
o 7% reported that they were unable to work due to their arthritis. 
o 5% reported that they needed frequent time off work. 
o 16% and 37% respectively reported that they occasionally and rarely needed time off 
work. 
o 42% reported that they had been asked about their work (49% in the South of 
England and in the Midlands and East of England; 30% in London) 
 
PREM data 
Table 6 summarises the PREM data received nationally and for NHS regions. As for the RAID and 
work data only a small number of RA patients (577) completed their questionnaires after 3 months of 
follow up; even when these questionnaires were returned the PREM question was not answered by 
17% of patients.  Nationally 78% of RA patients providing data agreed with the statement “overall in 
the last 3 months I have had a good experience of care for my arthritis” (87% in London and 76% in 
the South of England) and less than 2% disagreed or strongly disagreed. 
The national and NHS regional findings summarised above disguise considerable variation at 
individual trust level. 
 
Discussion 
This HQIP funded audit has allowed the first comprehensive national benchmarking of care given to 
people with newly diagnosed inflammatory arthritis for England and Wales. 
 
The population of patients recruited and the spread of confirmed diagnoses at first appointment were 
largely as anticipated, with the majority of patients with a confirmed diagnosis at recruitment having 
RA. 
 
As reported in the other linked paper [8] data quality was generally good. Data were collected from 
the vast majority of trusts but some trusts were unable to recruit anticipated numbers of patients. 
Missing data was a particular problem however for patient derived data and for some of the clinician 
derived follow up data and this should be borne in mind when interpreting the results. 
 
There were missing data for DAS 28 in only 9% of RA patients nationally at baseline indicating that 
the vast majority of clinicians are now calculating a DAS 28 for patients seen with RA within the 
context of the audit. Wales reported DAS 28 assessment for virtually all patients but rates were much 
lower in the South of England (85%). The variations in DAS 28 reporting may reflect variation in 
practice but could also be a reflection of data quality with higher levels of missing data in the South of 
England. Whilst regular assessment of disease activity including DAS 28 is considered good clinical 
practice it only becomes mandatory in the UK when patients need to be assessed for biologic therapy 
later in the disease course. To be eligible for biologics in the UK patients are required to have at least 
two DAS 28 of >5.1, assessed at least a month apart, despite use of at least two conventional 
DMARDs for at least 6 months. 
Nationally, and for each region, the highest proportion of RA patients with DAS 28 data available had 
severe or moderate disease activity at presentation (84% nationally). 
Patient derived disease activity measures were available for most EIA patients at baseline Although 
RAID is a validated tool for RA it assesses domains relevant to all inflammatory arthritis problems and 
was collected at baseline to ensure that scores were available for all patients that were later 
established with a diagnosis of RA. As with the clinician derived assessment (DAS 28) the RAID 
indicated a generally severe level of disease at the point of presentation to secondary care. . Ideally 
systems need to be implemented to help identify patients with EIA and allow them to be seen within 
specialist services before their disease has reached severe levels. There was no evidence for 
significant geographical variation in disease severity at the point of first specialist review but clinicians 
and patients in Wales reported the highest DAS 28 and RAID scores at baseline. The overall range of 
scores however was very wide indicating that, whilst the majority of patients presented with 
moderately severe disease, there were patients presenting with very mild but also with very severe 
disease. 
 
Missing data for DAS 28 at follow up hinders interpretation of the results. The available data show that 
nearly two thirds of patients achieved a meaningful reduction in DAS 28 and a quarter achieve 
remission after 3 months of specialist care and this suggests that treatments initiated for patients with 
RA are having impact in this relatively short time frame of specialist care for most patients. These 
results however also show that 11% of patients nationally still have severe disease activity after 3 
months of specialist care and this highlights scope for further improvement in the early management 
of RA in our patient population. 
 
A second RAID score was requested from all RA patients after 3 months of specialist care but 
baseline and follow up data were only available for 509 patients so again this limits interpretation of 
the results. Interestingly although average DAS 28 was the same across all NHS regions after 3 
months of follow up there was variation in the average RAID scores from 3.1 – 4.2. In addition, at 
population level, greater improvements in DAS 28 were not mirrored by similar improvements in 
RAID. For example Wales achieved a meaningful reduction in DAS 28 in the highest proportion of 
patients but also the lowest mean reduction in RAID score. The RAID score covers more holistic 
aspects of the impact of disease on an individual, including emotional well-being and coping than the 
DAS 28 and this may, in part explain this discrepancy. Further research into factors influencing 
response to treatment as recorded by DAS 28 and by RAID could improve our understanding of this 
particular result. 
The lack of a meaningfully clinically important reduction in RAID score for the majority of patients is 
disappointing and indicates scope for improvement in managing patient’s symptoms and coping 
strategies in the early stages of their disease. This maps to the failure of the majority of patients to 
achieve a previously set treatment target [8] and is important. An explanation for this may partly lie in 
the short follow up duration of the audit (acknowledging DMARD therapy often takes more than 3 
months to achieve full effect) and with issues around capacity to provide intensive review and 
treatment escalation. However, a further consideration is that RA has a serious impact upon function 
and performance, which may persist despite apparent control of the inflammatory burden (reflected in 
good DAS control). This observation highlights the need for rheumatologists to use tools beyond 
simply the DAS 28, or other objective measures of inflammation such as joint ultrasound, when  
measuring treatment response. Indeed, measures of pain, fatigue and physical function are perhaps 
the most relevant outcomes for patients, despite being poorly captured in routine care. 
 
The impact of specific treatments (steroids, DMARDs),  on DAS 28 and  RAID score  has not been 
assessed as part of this audit but would be an important areas for future research. Whether patient 
education and support for self management influences components of the RAID score  is also worthy 
of exploration. 
 
Early arthritis most often presents in people of working age [11]. Over 70% of people recruited to this 
national audit were under 66 years of age. There is overwhelming evidence that established 
inflammatory arthritis has severe and often permanent effects on work capacity although there is 
some evidence that work retention is improving [12]. Health and social care interventions designed to 
keep people in work are therefore a crucial part of the effective management of inflammatory arthritis.  
Our data on work related outcomes are limited because so many participants did not answer the work 
related questions. However the existing data suggest that impact of work capability is small in the very 
early stages of EIA. This suggests that early disease may be a crucial time for work-related 
interventions, before work instability translates into long term work incapacity. The relationship 
between changing work status, demographic factors and clinical parameters would be of interest and 
worthy of future research. 
As emphasised by Dame Professor Carol Black, interventions around work will not happen unless 
questions about work are part of the clinical consultation [13]. Previous data suggest that providers of 
rheumatology services believe that those questions are asked [], but evidence from the National 
Rheumatoid Arthritis Society [14] suggests that the majority of patients do not recall being asked 
about work. Data from this National Audit echo the findings from the National Rheumatoid Arthritis 
Society, with only 42% of patients returning the work related questionnaire recalling being asked 
about work. Patient recall may be contributing to these statistics but these data suggest an aspect of 
care that can readily be improved and may in themselves act as a spur for including work issues in 
the clinical consultation. In support of this important component of patient care the BSR is working 
with Cardiff University to implement a regional training programme across the UK to encourage 
clinicians to discuss work issues within consultations. 
In the absence of a validated composite score for the PREM, the responses to the overarching 
question ‘overall in the past 3 months I have had a good experience of care for my arthritis’ has been 
reported. The low proportion of RA patients completing their PREM questionnaires after 3 months of 
follow up again limits the ability to draw any substantial conclusions from the data supplied. The low 
data return rate is disappointing as the PREM is an important source of information on how trusts are 
meeting the needs of their patients.  The low rate of data supply may relate to complexities linked with 
data collection processes. In order to protect patient confidentiality and encourage honest feedback 
completed paper questionnaires had to be returned to individuals not directly involved in the patient’s 
clinical care and then uploaded to the database. These confidential processes  may have impaired 
data capture. 
Nearly one fifth of RA patients failed to supply a response to the question analysed for this report 
when returning the PREM questionnaire and the reasons for this are unclear. The PREM 
questionnaire was originally developed and tested for use after 12 months of specialist care and was 
modified for use at 3 months for this audit. It is possible that patients did not feel able to provide the 
reasonably detailed feedback on their experiences after just 3 months of care. At the time of finalising 
the audit questionnaires, there were no alternative validated PREMs. 
The PREM data that are available are broadly re-assuring, however trusts are encouraged not to be 
complacent in interpreting these results. Of some reassurance only a small proportion of RA patients 
(1% nationally) reported that they disagreed or strongly disagreed with the PREM question on overall 
quality of care. Trusts receiving such feedback are, in particular, encouraged to examine the full detail 
of the PREM data, to explore mechanisms for gaining further feedback from patients and to review 
aspects of service provision that may impact upon patient experience. 
Overall this national audit has provided clinicians with  feedback on clinician and patient reported 
outcomes, including information on ability to work, for their patients with RA and this is the first time 
such data has been available with national and regional benchmarking. In addition some limited 
feedback on patient experience of rheumatology specialist services has been obtained. This audit has 
highlighted the difficulties in obtaining data within busy clinic settings and in particular highlights the 
difficulties in obtaining important patient derived information in such settings. 
The audit has revealed a clear need for the NHS to develop better systems for capturing, coding and 
integrating information from outpatient clinics, including measures of patient experience and outcome 
and measures of ability to work. 
This audit is on-going and further research using the data collected should help improve our 
understanding of the factors that influence outcome for patients with an EIA and RA.  
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